Table 1.
Baseline characteristics of the overall study population and by cohort.
| COHORTS | |||||
|---|---|---|---|---|---|
| Participant Characteristics- | Total Population | COLON | EnCoRe | CORSA | ColoCare |
| Number of participants | 440 | 135 | 137 | 26 | 142 |
| Sex, n (%) | |||||
| Male | 282 (64%) | 76 (56%) | 86 (63%) | 22 (84%) | 98 (69%) |
| Female | 158 (36%) | 59 (44%) | 51 (37%) | 4 (16%) | 44 (31%) |
| Age at diagnosis, years (median, range) | 66.0 (27.0–88.0) | 66.0 (31.0–84.0) | 67.0 (36.0–87.0) | 69.5 (39.0–88.0) | 64.0 (27.0–86.0) |
| Body mass index * | |||||
| Continuous, kg/m2 (median, range) | 26.3 (17.2–46.0) | 25.4 (17.2–40.2) | 27.2 (19.0–46.0) | 26.4 (21.0–35.9) | 26.2 (17.8–39.7) |
| Underweight, <18.5, n (%) | 5 (1%) | 3 (2%) | 2 (1%) | ||
| Normal weight, 18.5–24.9, n (%) | 143 (33%) | 57 (44%) | 36(26%) | 6 (26%) | 44 (31%) |
| Overweight, 25–29.9, n (%) | 192 (45%) | 52 (40%) | 58 (43%) | 13 (57%) | 69 (49%) |
| Obese, ≥30, n (%) | 92 (21%) | 19 (14%) | 42 (31%) | 5 (17%) | 26 (19%) |
| Tumor stage, n (%) | |||||
| II | 187 (43%) | 66 (49%) | 45 (33%) | 13 (50%) | 63 (44%) |
| III | 253 (57%) | 69 (51%) | 92 (67%) | 13 (50%) | 79 (56%) |
| Tumor location 1, n (%) | |||||
| Colon cancer | 248 (57%) | 86 (64%) | 81 (59%) | 17 (71%) | 64 (45%) |
| Distal colon | 129 (30%) | 44 (33%) | 39 (28%) | 10 (42%) | 36 (25%) |
| Proximal colon | 119 (27%) | 42 (31%) | 42 (31%) | 7 (29%) | 28 (20%) |
| Rectal cancer | 190 (43%) | 49 (36%) | 56 (41%) | 7 (29%) | 78 (55%) |
| Neo-adjuvant treatment, n (%) | |||||
| Yes | 306 (70%) | 91 (67%) | 90 (66%) | 25 (96%) | 100 (70%) |
| No | 134 (30%) | 44 (33%) | 47 (34%) | 1 (4%) | 42 (30%) |
| Adjuvant treatment, n (%) | |||||
| Yes | 183 (42%) | 42 (32%) | 64 (47%) | 12 (46%) | 65 (47%) |
| No | 249 (58%) | 90 (68%) | 73 (53%) | 14 (54%) | 72 (53%) |
| Follow-up time (months), median, range) | |||||
| Patients with recurrence | 19.9 (3.6–81.0) | 27.1 (7.0–81.0) | 15.0 (3.7–45.1) | 46.7 (39.0–65.8) | 15.7 (3.6–45.6) |
| Patients without recurrence | 42.2 (3.6–88.8) | 71.2 (9.3–88.8) | 41.9 (4.1–69.1) | 44.9 (3.6–70.1) | 31.5 (3.6–65.8) |
| Recurrence 2, n (%) | |||||
| Yes | 69 (15%) | 20 (15%) | 23 (17%) | 6 (23%) | 20 (14%) |
| Early Recurrence 3 | 44 (64%) | 8 (40%) | 18 (78%) | 18 (90%) | |
| Late Recurrence 4 | 25 (36%) | 12 (60%) | 5 (22%) | 6 (100%) | 2 (10%) |
| No | 371 (85%) | 115 (85%) | 114 (83%) | 20 (77%) | 122 (86%) |
* Body Mass Index (BMI) in all cohorts was based on self-reported height and weight. Except, in the ENCORE cohort height and weight have been assessed by a trained dietician. 1 Tumor location is defined as colon (cecum, appendix and ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon and sigmoid colon) and rectal (rectosigmoid junction and rectum) cancer. 2 Recurrence is defined as colorectal cancer recurrence (event) in patients who had complete tumor resection. 3 Early recurrence is defined as recurrence <= 24 months after diagnosis. 4 Late recurrence is defined as recurrence that occurs >24 months after diagnosis.